Reply: Letter to the Editor: About the advantages and disadvantages of discrete-event simulation for health economic analyses [0.03%]
致编辑的回信：关于离散事件模拟在卫生经济学分析中的利弊
J Jaime Caro,Jörgen Möller
J Jaime Caro
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations [0.03%]
欧洲医学肿瘤学会临床效益规模（ESMO-MCBS）在表皮生长因子受体活化突变的晚期非小细胞肺癌一线治疗酪氨酸激酶抑制剂关键III期随机对照试验中的应用
Jacopo Giuliani,Andrea Remo,Andrea Bonetti
Jacopo Giuliani
To examine the magnitude of the clinical benefit from first-line tyrosine kinase inhibitors (TKIs) advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR)-mutations. Areas covered: The present eva...
Simon B Zeichner,Christine G Kohn,Daniel A Goldstein
Simon B Zeichner
Despite its FDA approval and incorporation into the National Comprehensive Cancer Network (NCCN) treatment guidelines, ramucirumab (RAM) is associated with a drug acquisition cost that is substantially higher than other approved options. Gi...
Cost-effectiveness of professional pharmacy services in community pharmacy: a systematic review [0.03%]
社区药房专业药学服务的成本效益系统评价
A Malet-Larrea,V García-Cárdenas,L Sáez-Benito et al.
A Malet-Larrea et al.
The aim was to determine whether professional pharmacy services (PPS) provided to ambulatory patients attending community pharmacy are cost-effective compared with usual care (UC). Areas covered: MEDLINE, Web of Knowledge, Scopus, Cochrane ...
Outcome of the second Medicines Utilisation Research in Africa Group meeting to promote sustainable and appropriate medicine use in Africa [0.03%]
推动非洲合理用药的第二届医药利用研究非洲小组会议成果
Amos Massele,Johanita Burger,Francis Kalemeera et al.
Amos Massele et al.
The second Medicines Utilization Research in Africa (MURIA) group workshop and symposium again brought researchers together from across Africa to improve their knowledge of drug utilization (DU) methodologies and exchange ideas to further p...
How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3) [0.03%]
如何开展为医疗决策提供依据的经济学评价系统评审（一）——五步工作法
Ghislaine A P G van Mastrigt,Mickaël Hiligsmann,Jacobus J C Arts et al.
Ghislaine A P G van Mastrigt et al.
Systematic reviews of economic evaluations are useful for synthesizing economic evidence about health interventions and for informing evidence-based decisions. Areas covered: As there is no detailed description of the methods for performing...
How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3) [0.03%]
临床实践指南的系统评价之经济评估的选择与检索策略开发（第2部分）
F W Thielen,Gapg Van Mastrigt,L T Burgers et al.
F W Thielen et al.
This article is part of the series "How to prepare a systematic review of economic evaluations (EES) for informing evidence-based healthcare decisions", in which a five-step approach is proposed. Areas covered: This paper focuses on the sel...
How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3) [0.03%]
如何开展经济学评价的系统评价（III）：资料提取、偏倚风险和适用性评估
Bfm Wijnen,Gapg Van Mastrigt,W K Redekop et al.
Bfm Wijnen et al.
This article is part of the series "How to Prepare a Systematic Review (SR) of Economic Evaluations (EE) for Informing Evidence-based Healthcare Decisions" in which a five-step-approach for conducting a SR of EE is proposed. Areas covered: ...
Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance [0.03%]
中国城镇职工基本医疗保险制度下监管竞争对医药价格的影响分析
Mingyue Zhao,Jing Wu
Mingyue Zhao
Background: Examine the effects of regulated competition on the drug pricing in China. Methods: Based on product-level data, a regressi...
Taehwan Park,Chang-Ju Choi,Yeera Choi et al.
Taehwan Park et al.
Cetuximab is a novel biological agent with superior therapeutic efficacy for colorectal cancer treatment. This study aimed to systematically review the existing evidence related to the cost-effectiveness of cetuximab. Areas covered: Using M...